Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02181231 · ClinicalTrials.gov registry record · Phase 1
Buprenorphine Used With Treatment Resistant Depression in Older Adults
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02181231 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 18 participants.
The verdict
NCT02181231, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The investigators are conducting a research study to learn about the safety and benefit of using a medication called buprenorphine for patients with difficult to treat depression. This research study is testing whether combining two medications will be effective in treating depression when initial treatment with just one antidepressant does not relieve the depressive symptoms; this is what is called "difficult to treat depression" or "treatment resistant depression". The two medications the investigators are using are: an anti-depressant medication called venlafaxine extended release (venlafaxine XR), which is the generic form of Effexor, and buprenorphine. Buprenorphine is a medication that is FDA approved for the treatment of opioid dependence. The investigators are testing whether adding buprenorphine to venlafaxine XR enhances treatment response.
Interventions
- DRUG Placebo
- DRUG buprenorphine
- DRUG venlafaxine XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-06-01 |
| Est. Completion | 2018-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02181231
The ClinicalTrials.gov registry entry for NCT02181231 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02181231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02181231 about?
NCT02181231 is a clinical study titled "Buprenorphine Used With Treatment Resistant Depression in Older Adults". The investigators are conducting a research study to learn about the safety and benefit of using a medication called buprenorphine for patients with difficult to treat depression. This research study is testing whether combining two medications will be effective in treating depression when initial t...
What is the current status of trial NCT02181231?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2016-06-01. Estimated completion is 2018-04-30.
What interventions are being tested in trial NCT02181231?
The interventions under investigation include: Placebo (DRUG), buprenorphine (DRUG), venlafaxine XR (DRUG).
Who is sponsoring clinical trial NCT02181231?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.